LY 2784544

LY 2784544 Basic information
Product Name:LY 2784544
Synonyms:LY2784544(gandotinib);3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[;3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine;LY 2784544;3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine;3-(4-chloro-2-fluorobenzyl)-2-Methyl-N-(3-Methyl-1H-pyrazol-5-yl)-8-(MorpholinoMethyl)iMidazo[1,2-b]pyridazin-6-aMine;LY2784544/LY-2784544;IMidazo[1,2-b]pyridazin-6-aMine, 3-[(4-chloro-2-fluorophenyl)Methyl]-2-Methyl-N-(5-Methyl-1H-pyrazol-3-yl)-8-(4-MorpholinylMethyl)-
CAS:1229236-86-5
MF:C23H25ClFN7O
MW:469.94
EINECS:
Product Categories:Inhibitors;JAK;STAT;Inhibitor;JAK/STAT
Mol File:1229236-86-5.mol
LY 2784544 Structure
LY 2784544 Chemical Properties
density 1.45
storage temp. Store at -20°C
solubility ≥23.5 mg/mL in DMSO; insoluble in H2O; ≥5.65 mg/mL in EtOH with gentle warming and ultrasonic
form solid
pka14.12±0.10(Predicted)
Safety Information
MSDS Information
LY 2784544 Usage And Synthesis
UsesLY2784544 is a JAK2 inhibitor. LY2784544 may be used as a potential treatment for patients with myeloproliferative neoplasm.
DefinitionChEBI: Gandotinib is a member of pyridazines.
targetwild-type JAK2
LY 2784544 Preparation Products And Raw materials
Raw materials6-chloro-3-(4-chloro-2-fluorobenzyl)-2-Methyl-8-(Morpholin-4-ylMethyl)iMidazo[1,2-b]pyridazine
Preparation ProductsLY-2784544 (HCl)
LY 294002 HYDROCHLORIDE Fedratinib (SAR302503, TG101348) Momelotinib (S)-3-fluoro-4-(4-((2-(3-fluorophenyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide LY 88074 LY-364947 PD 0325901 LY2409881 trihydrochloride Tozasertib LY2584702 LY3214996 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol Etalocib LY2228820 LY 2606368 LY-2562175 LY2828360 LY-2940094

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.